Aminopterin - Genzyme Oncology
Alternative Names: Aminopterin sodiumLatest Information Update: 24 Sep 2021
At a glance
- Originator ILEX Oncology Inc
- Developer Genzyme Oncology
- Class Antipsoriatics; Benzamides; Glutamates; Pterins; Small molecules
- Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Endometrial cancer; Leukaemia
Most Recent Events
- 18 Sep 2018 Genzyme withdraws a phase II trial for Endometrial Cancer prior to enrolment in USA, before September 2018 (NCT00003821)
- 31 Dec 2010 No development reported - Phase-II for Endometrial cancer in USA (PO)
- 31 Dec 2010 No development reported - Phase-II for Leukaemia in USA (IV)